Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Updates in Nephrology: Glomerular Diseases
Presented by: Syeda Ahmad, MD

Nephrology Year in Review: Hypertension, SGLTi, & Precision Medicine
Presented by: Cary Boyd-Shiwarski, MD, PhD

Educational Objectives:

Upon completion of this activity, participants should be able to:

Describe the novel treatment options for lupus nephritis and outcomes.
Review the implications of antigens in treatment of membranous
Describe the role of antigens in membranous nephropathy
Explain the role of technique to discover new antigens in membranous nephropathy
Review lupus nephritis
Define the blood pressure goals for patients with and without CKD
Explore the use of SGLT2i in patients with CKD
Implement genetic testing in a nephrology clinic

Suggested Additional Reading & Joint Accreditation Statement - Note: This Accreditation Statement Supersedes All Other Statements:

Suggested additional reading:

SPRINT trial final report (NEJM 2021) PMID: 34010531
KDIGO 2021 Guidelines (Kid Int 2021) PMID: 33637203
DAPA CKD (NEJM 2020 & 2021) PMID: 32970396 & 33503362
Groopman et al (NEJM 2019) PMID: 30586318
Jayasinghe et al (2021 Genet Med) PMID: 32939031
Furie R, Rovin BH,et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020 Sep 17;383(12):1117-1128. doi: 10.1056/NEJMoa2001180. PMID: 32937045.
Rovin BH, Teng YKO, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 May 29;397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-X. Epub 2021 May 7. Erratum in: Lancet. 2021 May 29;397(10289):2048. PMID: 33971155.
Sethi S, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 2020 Jan;97(1):163-174. doi: 10.1016/j.kint.2019.09.014. Epub 2019 Oct 7. PMID: 31901340.
AJKD Core Curriculum Membranous Nephropathy American Journal of Kidney Diseases Vol. 77Issue 3p440–453 Published online: January 21, 2021
Update on lupus nephritis American Journal of Kidney DiseasesVol. 76Issue 2p265–281Published online: March 24, 2020

Joint Accreditation Statement
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit[s]™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This educational activity is approved for 1.0 contact hours.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Authors:

Cary Boyd-Shiwarski, MD, PhD — Assistant Professor of Medicine, Renal-Electrolyte Division University of Pittsburgh School of Medicine
Dr. Boyd-Shiwarski is a consultant with the Sanofi-Genzyme Rare Disease Program.

Syeda Ahmad, MD — Assistant Professor of Medicine, Renal-Electrolyte Division
Medical Director, Glomerular Disease Center, University of Pittsburgh School of Medicine
No relationships with industry relevant to the content of this educational activity have been disclosed.

No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The University of Pittsburgh is an affirmative action, equal opportunity institution.